CAR-ENGINEERED PRIMARY NK CELLS SHOW PROMISING EFFECTS AS TARGETED THERAPY AGAINST EGFR-POSITIVE GLIOBLASTOMA

被引：0
|
作者：
Roller, B. [1 ,2 ]
Reindl, L. [2 ,3 ]
Strassheimer, F. [1 ,2 ]
Ziegener, L. [1 ,2 ]
Elleringmann, P. [1 ,2 ]
Kiefer, A. [4 ]
Roeder, J. [2 ,4 ]
Steinbach, J. [1 ,2 ]
Wels, W. [2 ,4 ]
Ullrich, E. [3 ]
Burger, M.
机构：
[1] Dr Senckenberg Inst Neurooncol, Frankfurt, Germany
[2] Goethe Univ Frankfurt, Frankfurt Canc Inst FCI, Frankfurt, Germany
[3] Goethe Univ, Childrens Hosp, Frankfurt, Germany
[4] Georg Speyer Haus, Inst Tumor Biol & Expt Therapy, Frankfurt, Germany
来源：
NEURO-ONCOLOGY | 2024年 / 26卷
关键词：
D O I：
10.1093/neuonc/noae144.217
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P12.04.A
引用
收藏
页码：V66 / V66
页数：1
相关论文
共 50 条
  • [21] Focusing on NK cells and ADCC: A promising immunotherapy approach in targeted therapy for HER2-positive breast cancer
    Li, Feifei
    Liu, Sheng
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [22] Therapeutic effects against high-grade glioblastoma mediated by engineered induced neural stem cells combined with GD2-specific CAR-NK
    Liu, Weihua
    Zhao, Yu
    Liu, Zhongfeng
    Zhang, Guangji
    Wu, Huantong
    Zheng, Xin
    Tang, Xihe
    Chen, Zhiguo
    CELLULAR ONCOLOGY, 2023, 46 (06) : 1747 - 1762
  • [23] Therapeutic effects against high-grade glioblastoma mediated by engineered induced neural stem cells combined with GD2-specific CAR-NK
    Weihua Liu
    Yu Zhao
    Zhongfeng Liu
    Guangji Zhang
    Huantong Wu
    Xin Zheng
    Xihe Tang
    Zhiguo Chen
    Cellular Oncology, 2023, 46 : 1747 - 1762
  • [24] Adoptive Therapy of Ewing Sarcoma with GD2 Antigen-Specific Car-Engineered NK Cells Induces Upregulation of Immune-Inhibitory HLA-G
    Rossig, C.
    Kailayangiri, S.
    Altvater, B.
    Spurny, C.
    Jamitzky, S.
    Schelhaas, S.
    Wiek, C.
    Hanenberg, H.
    Hartmann, W.
    Wiendl, H.
    Meltzer, J.
    Farwick, N.
    Greune, L.
    PEDIATRIC BLOOD & CANCER, 2016, 63 : S38 - S38
  • [25] Primary CAR-NK cells targeting B7-H3 as a novel experimental immunotherapeutic strategy against glioblastoma
    Thul, S.
    Reindl, L. M.
    Wendel, P.
    Burger, M. C.
    Steinbach, J. P.
    Wels, W. S.
    KLINISCHE PADIATRIE, 2024, 236 (03): : 215 - 215
  • [26] Anti-Mesothelin CAR-NK cells as a novel targeted therapy against cervical cancer ( vol 15, 1485461, 2024)
    Kutle, Ivana
    Polten, Robert
    Stalp, Jan Lennart
    Hachenberg, Jens
    Todzey, Felix
    Hass, Ralf
    Zimmermann, Katharina
    von der Ohe, Juliane
    von Kaisenberg, Constantin
    Neubert, Lavinia
    Kamp, Jan C.
    Schaudien, Dirk
    Seyda, Ann-Kathrin
    Hillemanns, Peter
    Klapdor, Ruediger
    Morgan, Michael Alexander
    Schambach, Axel
    FRONTIERS IN IMMUNOLOGY, 2025, 16
  • [27] AAV-mediated gene transfer of a checkpoint inhibitor in combination with HER2-targeted CAR-NK cells as experimental therapy for glioblastoma
    Strecker, M., I
    Wlotzka, K.
    Strassheimer, F.
    Roller, B.
    Ludmirski, G.
    Konig, S.
    Roder, J.
    Opitz, C.
    Alekseeva, T.
    Reul, J.
    Sevenich, L.
    Tonn, T.
    Wels, W. S.
    Steinbach, J. P.
    Buchholz, C. J.
    Burger, M. C.
    ONCOIMMUNOLOGY, 2022, 11 (01):
  • [28] Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activity
    E Liu
    Y Tong
    G Dotti
    H Shaim
    B Savoldo
    M Mukherjee
    J Orange
    X Wan
    X Lu
    A Reynolds
    M Gagea
    P Banerjee
    R Cai
    M H Bdaiwi
    R Basar
    M Muftuoglu
    L Li
    D Marin
    W Wierda
    M Keating
    R Champlin
    E Shpall
    K Rezvani
    Leukemia, 2018, 32 : 520 - 531
  • [29] A novel nanobody as therapeutics target for EGFR-positive colorectal cancer therapy: exploring the effects of the nanobody on SW480 cells using proteomics approach
    Lamtha, Thomanai
    Krobthong, Sucheewin
    Yingchutrakul, Yodying
    Samutrtai, Pawitrabhorn
    Gerner, Christopher
    Tabtimmai, Lueacha
    Choowongkomon, Kiattawee
    PROTEOME SCIENCE, 2022, 20 (01)
  • [30] Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activity
    Liu, E.
    Tong, Y.
    Dotti, G.
    Shaim, H.
    Savoldo, B.
    Mukherjee, M.
    Orange, J.
    Wan, X.
    Lu, X.
    Reynolds, A.
    Gagea, M.
    Banerjee, P.
    Cai, R.
    Bdaiwi, M. H.
    Basar, R.
    Muftuoglu, M.
    Li, L.
    Marin, D.
    Wierda, W.
    Keating, M.
    Champlin, R.
    Shpall, E.
    Rezvani, K.
    LEUKEMIA, 2018, 32 (02) : 520 - 531
12345